Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder (DBS OUD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03950492
Recruitment Status : Recruiting
First Posted : May 15, 2019
Last Update Posted : October 11, 2019
Sponsor:
Collaborators:
National Institute on Drug Abuse (NIDA)
Medtronic
Information provided by (Responsible Party):
Ali Rezai, West Virginia University

Brief Summary:
The purpose of this clinical study is to investigate the safety, tolerability, and feasibility of Deep Brain Stimulation (DBS) of the nucleus accumbens (NAc) and ventral internal capsule (VC) for participants with treatment refractory opioid use disorder (OUD) who have cognitive, behavioral, and functional disability. This study will also provide critical information for planning subsequent clinical trials.

Condition or disease Intervention/treatment Phase
Opioid-Related Disorders Device: Deep Brain Simulator Not Applicable

Detailed Description:
The overarching goal of this study is to evaluate the safety, tolerability, feasibility and impact on outcomes of NAc/VC DBS for treatment refractory OUD. In treatment refractory OUD, innovative approaches and more invasive interventions including DBS are warranted to improve outcomes.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 4 participants
Intervention Model: Single Group Assignment
Intervention Model Description: This is an open-label, safety, tolerability, and feasibility study for participants who have treatment refractory OUD that are eligible to have deep brain stimulation (DBS) targeting the NAc/VC.
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory
Actual Study Start Date : October 1, 2019
Estimated Primary Completion Date : December 30, 2020
Estimated Study Completion Date : December 29, 2021

Arm Intervention/treatment
Experimental: OUD DBS
This is a single arm study. Participants will be followed in an inpatient service for two weeks to gather baseline data followed by DBS placement and up to 6 weeks inpatient for clinical stabilization and DBS titration. All participants will then be followed twice a week for 12 weeks in the outpatient setting and then once a week for a total of 52 weeks post-titration.
Device: Deep Brain Simulator
This is an open-label, safety, tolerability, and feasibility study for participants who have treatment refractory OUD that are eligible to have DBS targeting the NAc/VC.




Primary Outcome Measures :
  1. Incidence of Study-Emergent Adverse Events [ Time Frame: 24 - 52 weeks ]
    Study participants will be closely monitored for adverse events following DBS surgery with regular check-ups by study personnel.

  2. Change in Opioid Use [ Time Frame: 24 - 52 weeks ]
    Opioid use as measured by quantitative urine toxicology via high pressure liquid chromatography.


Secondary Outcome Measures :
  1. Participant Survival [ Time Frame: 12 -52 weeks ]
    Incidence of drug overdose deaths among the participants.

  2. Treatment Retention [ Time Frame: 12 - 52 weeks ]
    Participants' retention in traditional medication assisted treatment (MAT).

  3. Incidence of Serious Infectious Disease Complications [ Time Frame: 12 - 52 weeks ]
    Laboratory tests and evaluation to discern presentation of infectious disease.

  4. Mood, Craving and Executive Function [ Time Frame: 12 and 24 weeks post surgery ]
    Participants will complete standardized measures of mood, drug craving, and executive function at 12 weeks and 24 weeks post DBS titration.


Other Outcome Measures:
  1. Frontal Lobe Metabolism [ Time Frame: 3 weeks and 12 weeks post surgery ]
    18fluoro-Deoxy-Glucose (FDG) PET will be use to determine if there is an increase in frontal lobe metabolism following DBS

  2. Changes in Dopamine [ Time Frame: 3 weeks and 12 weeks post surgery ]
    C11 Raclopride PET may be used to examine for changes in dopamine at 12 weeks post titration.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Fulfills current DSM-5 (American Psychiatric Association Diagnostic and statistical manual of mental disorders, 5th ed, 2013) diagnostic criteria for OUD (severe) and at least a 5-year history.
  • Participants may have comorbid SUD diagnoses at mild, moderate or severe levels, however OUD must be the primary disorder for which the individual is seeking treatment and the other use disorders must occur in the context of relapse
  • Failed at least two levels of treatment (outpatient/Comprehensive Opioid Addiction Treatment (COAT), intensive outpatient/intensive COAT, residential, inpatient, Adult Intensive Outpatient Program (AIOP), Dual Diagnosis Unit (DDU), which included buprenorphine/naloxone.
  • At least two overdose survivals or one overdose survival and one life-threatening infectious disease complication with relapse after treatment (e.g., endocarditis with valve repair/replacement) within the past 1 year.
  • Family/Social Support/Involvement (as assessed via the Multidimensional Scale of Perceived Social Support).
  • Is able to provide informed consent.

Exclusion Criteria:

  • Medical problems requiring intensive medical or diagnostic management.
  • Diagnosis of acute myocardial infarction or cardiac arrest within the previous 6 months.
  • History of a neurosurgical ablation procedure.
  • Any medical contraindications to undergoing DBS surgery.
  • History of hemorrhagic stroke.
  • Life expectancy of <3 years
  • Past or present diagnosis of schizophrenia, psychotic disorder, bipolar disorder, or untreated depression other than one determined to be substance induced (assessed via SCID-5). Any treated depression has to have been in remission for one year.
  • Baseline assessment on the Hamilton Depression Rating Scale (HAMD) of greater than 17 or increased risk of suicide based upon any positive response on the Columbia Suicide Severity Scale.
  • Cluster A or B Personality Disorders.
  • Diagnosis of dementia.
  • History of neurological disorder.
  • History of previous neurosurgery (brain) or head trauma.
  • History of suicide attempt.
  • Parental history of completed suicide.
  • Abnormal coagulation lab studies or uncontrolled hypertension.
  • Implanted neurostimulators.
  • Any current CNS infection or infection with the Human Immunodeficiency Virus (HIV).
  • Unable to undergo MR-imaging.
  • Documentation of MRI abnormality indicative of a neurological condition.
  • Substance abuse treatment mandated by court of law.
  • Pregnant or planning to become pregnant.
  • Conditions requiring diathermy.
  • Anticoagulant treatment.
  • Primary language other than English.
  • Any evidence of systemic infection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03950492


Contacts
Layout table for location contacts
Contact: Marc Haut, PhD 304-293-6276 mhaut@hsc.wvu.edu
Contact: Barbara Harring 304-293-9638 barbara.harring@hsc.wvu.edu

Locations
Layout table for location information
United States, West Virginia
West Virginia University Rockefeller Neuroscience Institute Recruiting
Morgantown, West Virginia, United States, 26506
Contact: Marc W Haut, PhD    304-293-6276    mhaut@hsc.wvu.edu   
Contact: Barbara Harring    304-293-9638    barbara.harring@hsc.wvu.edu   
Sponsors and Collaborators
West Virginia University
National Institute on Drug Abuse (NIDA)
Medtronic
Investigators
Layout table for investigator information
Principal Investigator: Ali R Rezai, MD West Virginia University

Layout table for additonal information
Responsible Party: Ali Rezai, Principal Investigator, West Virginia University
ClinicalTrials.gov Identifier: NCT03950492     History of Changes
Other Study ID Numbers: 1903499841
1UG3DA047714-01 ( U.S. NIH Grant/Contract )
First Posted: May 15, 2019    Key Record Dates
Last Update Posted: October 11, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Keywords provided by Ali Rezai, West Virginia University:
Deep Brain Stimulation
Additional relevant MeSH terms:
Layout table for MeSH terms
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders